Skip to main content
Retour
Watch Compare

ADIAL PHARMACEUTICALS, INC.

Qualité des données : 83%
ADIL
NASDAQ Manufacturing Chemicals
1,62 €
▲ 0,04 € (2,53%)
6 months return
—
Momentum
Neutral
ROE
-158,03%

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-158,03%
En dessous de la moyenne du secteur (-54,47%)
ROIC-122,06%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio4,34
Interest CoverageN/A

Valorisation

PE (TTM|NTM)
-0,28 | -0,33
Au-dessus de la moyenne du secteur (-1,50)
P/B Ratio0,49
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -6,49 M

Price History

Tendances Financières

Objectif de Cours des Analystes

3 analystes
Buy
+1340.3%
upside to target
Actuel
1,62 €
Consensus Target
23,33 €
8,00 €
Bas
42,00 €
Haut
Prévisions
P/E Prévisionnel
-0,33
BPA Prévisionnel
-4,80 €
CA Est.
0,0

Surprises de Résultats

EPS
Reported Estimate Forecast
Next: Q1 2026 · EPS Est: -2,25 € · Rev Est: 0,0
Q12025 Q22025 Q32025 Q42025 Q1 '26 Q2 '26
Reported -8,50 € -4,50 € -2,00 € -11,48 € — —
Estimate -12,38 € -5,50 € -3,50 € -2,13 € -2,25 € -1,54 €
Surprise +31,31% +18,18% +42,86% -438,97% — —

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: -158,03% · Net Margin: N/A
Revenue (TTM) N/A Net Income (TTM) -7,98 M
ROE -158,03% ROA -128,03%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -6,49 M
ROIC -122,06% FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 4,34
Debt / Equity N/A Current Ratio 4,34
Interest Coverage N/A Asset Turnover N/A
Working Capital 3,86 M Tangible Book Value 4,50 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,28 · EV/EBITDA: N/A
P/E Ratio -0,28 Forward P/E -0,33
P/B Ratio 0,49 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -291,46%
Market Cap 2,23 M Enterprise Value -2,38 M

Per Share

EPS: -11,93 · FCF/Share: -4,55
EPS (Diluted TTM) -11,93 Revenue / Share N/A
FCF / Share -4,55 OCF / Share -4,55
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 81,39% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 81,39%
SBC-Adj. FCF -7,43 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -7,98 M -13,20 M -5,12 M -12,73 M -19,42 M
EPS (Diluted) -11,93 -2,72 -3,60 -0,51 —
Gross Profit — — — — —
Operating Income -7,80 M -8,28 M -6,89 M -13,32 M -19,29 M
EBITDA — — — — —
R&D Expenses 2,62 M 3,23 M 1,27 M 4,18 M 8,40 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax — — — -502,0 -94 077,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 6,67 M 5,04 M 4,74 M 5,73 M 7,47 M
Total Liabilities 1,40 M 975 858,0 653 076,0 2,46 M 3,97 M
Shareholders' Equity 5,28 M 4,07 M 4,08 M 3,28 M 3,51 M
Total Debt — — — — —
Cash & Equivalents 5,88 M 3,75 M 2,83 M 4,00 M 6,06 M
Current Assets 6,18 M 4,06 M 3,20 M 4,78 M 6,46 M
Current Liabilities 1,40 M 975 858,0 653 076,0 1,79 M 2,72 M

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -0,3 -1,5
P/B 0,5 1,6
ROE % -158,0 -54,5
Net Margin % — -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3